Clarity Pharmaceuticals (ASX:CU6) received an AU$11.1 million research and development tax incentive refund, inclusive of interest, as part of the Australian Federal Government's R&D Tax Incentive program, according to a Thursday Australian bourse filing.
The refund will support the company's further development of its Targeted Copper Theranostic (TCT) platform of products for various cancer indications.
The company has decided to prioritize the development of its two products related to diagnostic and therapeutic applications for prostate and breast cancer.
To focus on the aforementioned products, the company has closed trials for two of its prostate cancer and neuroblastoma-related products.
The company's shares rose 12% in recent Thursday trade.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。